Evidence map›Paper›PMID 39698781›Full record

ArticleAmerican journal of hematology2025

Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.

Nilanjan Ghosh, Toby A Eyre, Jennifer R Brown, Nicole Lamanna, Beenish S Manzoor, Catherine C Coombs, Hande H Tuncer, Chaitra Ujjani, Lori A Leslie, Lindsey E Roeker and 23 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Bruton's Tyrosine Kinase (BTK) Mutations in Chronic Lymphocytic Leukemia (CLL): A Clinical View.Mediterranean journal of hematology and infectious diseases · 2025
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Nilanjan GhoshLevine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, North Carolina, USA.ORCID https://orcid.org/0000-0002-3848-6136
Toby A EyreChurchill Hospital, Oxford University, Oxford, UK.
Jennifer R BrownDana-Farber Cancer Institute, Boston, Massachusetts, USA.
Nicole LamannaColumbia University, New York, New York, USA.
Beenish S ManzoorAbbVie Inc., North Chicago, Illinois, USA.
Catherine C CoombsUniversity of California Irvine, Irvine, California, USA.
Hande H TuncerDana-Farber Cancer Institute, Boston, Massachusetts, USA.
Chaitra UjjaniFred Hutchinson Cancer Research Center, Seattle, Washington State, USA.ORCID https://orcid.org/0000-0003-1977-1510
Lori A LeslieJohn Theurer Cancer Center, Hackensack Meridian Health, Hackensack, New Jersey, USA.
Lindsey E RoekerCLL Program, Leukemia Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Matthew S DavidsDana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0003-4529-2003
Joanna M RhodesRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
Alan P SkarbnikLymphoma and CLL Program, Novant Health Cancer Institute, Charlotte, North Carolina, USA.
Wendy SinaiAbbVie Inc., North Chicago, Illinois, USA.
Isabelle FleuryHôpital Maisonneuve-Rosemont, University of Montreal, Canada.
Brian T HillCleveland Clinic, Cleveland, Ohio, USA.
Nicolas Martinez-CalleNottingham University Hospitals, NHS Trust, Nottingham, UK.ORCID https://orcid.org/0000-0002-5184-9464
Paul M BarrWilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA.ORCID https://orcid.org/0000-0002-9733-401X
Dureshahwar JawaidAbbVie Inc., North Chicago, Illinois, USA.
Nnadozie EmechebeAbbVie Inc., North Chicago, Illinois, USA.
Laurie PearsonUniversity of Massachusetts, Worcester, Massachusetts, USA.
Frederick LansiganDartmouth Cancer Center, Lebanon, New Hampshire, USA.
Yun ChoiTufts Medical Center, Boston, Massachusetts, USA.
Christopher E JensenLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0002-6673-335X
Bita FakhriStanford Cancer Institute, Stanford University, Stanford, California, USA.
Deborah M StephensLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Steven E MarxAbbVie Inc., North Chicago, Illinois, USA.
Stephen J SchusterUniversity of Pennsylvania, Philadelphia, Pennsylvania, USA.
Michael CoyleLowell General Hospital, Lowell, Massachusetts, USA.
Irina PivnevaAnalysis Group Inc., Montreal, Quebec, Canada.
Talissa WatsonAnalysis Group Inc., Montreal, Quebec, Canada.
Annie GuerinAnalysis Group Inc., Montreal, Quebec, Canada.
Mazyar ShadmanFred Hutchinson Cancer Research Center, Seattle, Washington State, USA.ORCID https://orcid.org/0000-0002-3365-6562

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Physician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1M
AbbVieNCI NIH HHS P30 CA008748NCI NIH HHS T32 CA009172
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bruton tyrosine kinase inhibitorchronic lymphocytic leukemiareal‐world outcomesvenetoclax

Identifiers

PMID39698781
PMCPMC11803543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.